Adverse events680

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 680

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Randomized Period: Vandetanib Plus Pemetrexed	19	260	27
other	Anaemia	Blood and lymphatic system disorders	Randomized Period: Placebo Plus Pemetrexed	54	273	59
other	Anaemia	Blood and lymphatic system disorders	Survival Follow-up Period: Vandetanib Plus Pemetrexed	0	124	0
other	Anaemia	Blood and lymphatic system disorders	Survival Follow-up Period: Placebo Plus Pemetrexed	1	110	1
other	Leukopenia	Blood and lymphatic system disorders	Randomized Period: Vandetanib Plus Pemetrexed	18	260	27
other	Leukopenia	Blood and lymphatic system disorders	Randomized Period: Placebo Plus Pemetrexed	17	273	22
other	Leukopenia	Blood and lymphatic system disorders	Survival Follow-up Period: Vandetanib Plus Pemetrexed	0	124	0
other	Leukopenia	Blood and lymphatic system disorders	Survival Follow-up Period: Placebo Plus Pemetrexed	0	110	0
other	Neutropenia	Blood and lymphatic system disorders	Randomized Period: Vandetanib Plus Pemetrexed	21	260	32
other	Neutropenia	Blood and lymphatic system disorders	Randomized Period: Placebo Plus Pemetrexed	26	273	35
other	Neutropenia	Blood and lymphatic system disorders	Survival Follow-up Period: Vandetanib Plus Pemetrexed	0	124	0
other	Neutropenia	Blood and lymphatic system disorders	Survival Follow-up Period: Placebo Plus Pemetrexed	0	110	0
other	Lacrimation Increased	Eye disorders	Randomized Period: Vandetanib Plus Pemetrexed	12	260	12
other	Lacrimation Increased	Eye disorders	Randomized Period: Placebo Plus Pemetrexed	14	273	16
other	Lacrimation Increased	Eye disorders	Survival Follow-up Period: Vandetanib Plus Pemetrexed	0	124	0
other	Lacrimation Increased	Eye disorders	Survival Follow-up Period: Placebo Plus Pemetrexed	0	110	0
other	Abdominal Pain	Gastrointestinal disorders	Randomized Period: Vandetanib Plus Pemetrexed	16	260	21
other	Abdominal Pain	Gastrointestinal disorders	Randomized Period: Placebo Plus Pemetrexed	15	273	17
other	Abdominal Pain	Gastrointestinal disorders	Survival Follow-up Period: Vandetanib Plus Pemetrexed	1	124	1
other	Abdominal Pain	Gastrointestinal disorders	Survival Follow-up Period: Placebo Plus Pemetrexed	2	110	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00418886/events

API reference For AI assistants

Adverse events680

Sources 3

Read this list from software.